多哥妇女的乳腺癌：免疫组织化学亚型。
Breast cancer in togolese women: immunohistochemistry subtypes.
机构信息
Department of Oncology, Sylvanus Olympio University Teaching Hospital, BP 57, Lomé, Togo.
Department of Pathology, University Teaching Hospital of Lomé, BP 57, Lomé, Togo.
出版信息
BMC Womens Health. 2020 Nov 23;20(1):261. doi: 10.1186/s12905-020-01130-2.
BACKGROUND
Molecular classification of breast cancer is an important factor for prognostic and clinical outcomes. There are no data regarding molecular breast cancer subtypes among Togolese women. The objective of this study was to evaluate the expression of ER, PR, HER2, and molecular subtypes of breast cancer receptors in Togolese patients and to establish the correlation between clinical and histological data and molecular types.
METHODS
Clinicopathologic data of patients were collected from clinical records. Immunohistochemistry biomarkers (ER, PR, and HER2) were assessed in patients who have been diagnosed with invasive breast cancer from March 2016 to March 2020 in the department of oncology. The analysis of variance and the Chi-square Test was used to analyze the data.
RESULTS
A total of 117 cases were collected. The mean age of patients was 52.05 ± 12.38 with an age range of 30 to 85 years. Half of the patients were over 50 years old and the majority (70.9%) was postmenopausal. More than half of patients (52.1%) presented with T3-T4tumors.The most common histologic subtype of breast cancer was invasive ductal carcinoma of no special type (95.7%). Tumors grade 2 were predominant (51.3%) followed by grade 3 (42.7%). Advanced carcinomas were found in 69 patients (59%). The percentage of ER+, PR+, and HER2 positive tumors was 54.7%, 41%, and 15.4% respectively. The predominant molecular subtype was Triple negative (37.6%), followed by Luminal A (30.8.7%), Luminal B subtype (23.9%), and HER2 enriched (7.7%). There was a significant association between stage and breast cancer subtypes (p 0.025), histologic grade, and subtype (p < 0.0001) but no correlation was found with age, menopausal status, and tumor size.
CONCLUSION
Breast carcinoma in our patients are high grade tumors and are diagnosed at an advanced stage. Triple negative and Luminal A are the two predominant breast cancer subtypes in Togolese women. Consequently, Receptor testing availability should be a priority to offer the best breast cancer treatment.
背景
乳腺癌的分子分类是预测和临床结果的重要因素。目前尚无关于多哥妇女乳腺癌分子亚型的数据。本研究的目的是评估多哥患者中 ER、PR、HER2 受体的分子乳腺癌亚型的表达，并建立临床和组织学数据与分子类型之间的相关性。
方法
从临床记录中收集患者的临床病理数据。对 2016 年 3 月至 2020 年 3 月期间在肿瘤学系被诊断为浸润性乳腺癌的患者进行免疫组织化学生物标志物（ER、PR 和 HER2）评估。使用方差分析和卡方检验分析数据。
结果
共收集了 117 例病例。患者的平均年龄为 52.05 ± 12.38 岁，年龄范围为 30 至 85 岁。一半的患者年龄超过 50 岁，大多数（70.9%）处于绝经后状态。超过一半的患者（52.1%）表现为 T3-T4 期肿瘤。最常见的乳腺癌组织学亚型为非特殊类型浸润性导管癌（95.7%）。肿瘤分级 2 级占主导地位（51.3%），其次是 3 级（42.7%）。69 例患者为晚期癌（59%）。ER+、PR+和 HER2 阳性肿瘤的比例分别为 54.7%、41%和 15.4%。主要的分子亚型是三阴性（37.6%），其次是 Luminal A（30.8.7%）、Luminal B 亚型（23.9%）和 HER2 富集型（7.7%）。肿瘤分期与乳腺癌亚型之间存在显著相关性（p 0.025），组织学分级与亚型之间也存在显著相关性（p<0.0001），但与年龄、绝经状态和肿瘤大小无相关性。
结论
我们的患者中的乳腺癌是高级别肿瘤，且在晚期被诊断出来。三阴性和 Luminal A 是多哥妇女中两种主要的乳腺癌亚型。因此，受体检测的可用性应该是提供最佳乳腺癌治疗的优先事项。
Zotero 插件